Home > Financial Ratios > GLAND PHARMA

GLAND PHARMA
Core EBITDA Growth

    Back to All Ratios
GLAND PHARMA is part of below Screeners ↓
Top Small Cap Stocks with Best Fundamentals
Top Undervalued Small Cap Stocks
COMMUNITY POLL
for GLAND PHARMA
Please provide your vote to see the results

GLAND PHARMA Last 5 Year Core EBITDA Growth History

[Consolidated]

Mar2025Mar2024Mar2023Mar2022Mar2021
   Core EBITDA Growth(%) -1.3818.82-27.0420.6731.28

What is the latest Core EBITDA Growth ratio of GLAND PHARMA ?

The latest Core EBITDA Growth ratio of GLAND PHARMA is -1.38 based on Mar2025 Consolidated results.
Year Core EBITDA Growth
Mar2025-1.38
Mar202418.82
Mar2023-27.04
Mar202220.67
Mar202131.28

How is Core EBITDA Growth of GLAND PHARMA Trending?

Years Core EBITDA Growth % Change
Mar2025 -1.38
Negative
Mar2024 18.82
Positive
Mar2023 -27.04
Negative
Mar2022 20.67
-33.92
Mar2021 31.28 -

Other Financial Ratios of GLAND PHARMA


Compare Core EBITDA Growth ratio of peers of GLAND PHARMA

Peers & Returns Market Capitalization 1 Week 1 Month 1 Year
GLAND PHARMA ₹27,663.3 Cr -1.5% 1.5% 2.2% Stock Analytics
SUN PHARMACEUTICAL INDUSTRIES ₹401,541.0 Cr -3.6% -6.8% -5.6% Stock Analytics
DIVIS LABORATORIES ₹163,031.0 Cr -5.4% -2.4% 3.9% Stock Analytics
TORRENT PHARMACEUTICALS ₹138,451.0 Cr 3.6% 8.5% 23.5% Stock Analytics
CIPLA ₹112,377.0 Cr -5.1% -7.1% -3.5% Stock Analytics
DR REDDYS LABORATORIES ₹97,355.5 Cr -4.1% -8.3% -12.1% Stock Analytics


GLAND PHARMA Share Price vs Sensex


Share Price Returns(%) 1 Week 1 Month 1 Year
GLAND PHARMA

-1.5%

1.5%

2.2%

SENSEX

-0.4%

-1.7%

9.1%


You may also like the below Video Courses